Cargando…

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging. A biomodulatory therapy approach targeting the communicative infrastructure of HCC, including metronomic low-dose chemotherapy with capecitabine, pioglitazone and rofecoxib, has been evaluated in patients with non-cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, I., Schulz, U., Vogelhuber, M., Wiedmann, K., Endlicher, E., Klebl, F., Andreesen, R., Herr, W., Ghibelli, L., Hackl, C., Wiest, R., Reichle, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668342/ https://www.ncbi.nlm.nih.gov/pubmed/29098441 http://dx.doi.org/10.1007/s12032-017-1040-0

Ejemplares similares

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
por: Hart, Christina, et al.
Publicado: (2015)

Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
por: Hart, C., et al.
Publicado: (2015)

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
por: Heudobler, Daniel, et al.
Publicado: (2018)

Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
por: Heudobler, Daniel, et al.
Publicado: (2019)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
por: Schelker, Roland Christian, et al.
Publicado: (2018)

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
por: Heudobler, Daniel, et al.
Publicado: (2021)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

A Computational Model of Tumor Growth and Anakoinosis
por: Pantziarka, Pan, et al.
Publicado: (2019)

Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
por: Heudobler, Daniel, et al.
Publicado: (2021)

Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity
por: Heudobler, Daniel, et al.
Publicado: (2022)

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
por: Carta, Anna R., et al.
Publicado: (2011)

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
por: Rogue, Alexandra, et al.
Publicado: (2010)

Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches
por: Vallée, Alexandre, et al.
Publicado: (2018)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
por: Lamounier, Rodrigo N, et al.
Publicado: (2013)

Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions
por: Santin, José Roberto, et al.
Publicado: (2013)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
por: Vogelhuber, M., et al.
Publicado: (2014)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
por: Klobuch, Sebastian, et al.
Publicado: (2018)

Sustained relief of trigeminal neuropathic pain by a blood–brain barrier penetrable PPAR gamma agonist
por: Zhang, Morgan, et al.
Publicado: (2019)

Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction
por: Bruni, Emanuele, et al.
Publicado: (2018)

Effects of a PPAR -gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats
por: Tugrul, Ibrahim, et al.
Publicado: (2016)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma
por: Meyer, Stefanie, et al.
Publicado: (2010)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
por: Fante, Matthias A., et al.
Publicado: (2022)

Metronomics for thymic carcinoma
por: del Toro, Jacobo Muñoz, et al.
Publicado: (2014)

The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
por: Gray, Elizabeth, et al.
Publicado: (2012)

PPAR Gamma agonists regulate tobacco smoke-induced toll like receptor 4 expression in alveolar macrophages
por: Yin, Yan, et al.
Publicado: (2014)

PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes
por: Santambrogio, Paolo, et al.
Publicado: (2023)

PPAR-gamma agonist pioglitazone recovers mitochondrial quality control in fibroblasts from PITRM1-deficient patients
por: Di Donfrancesco, Alessia, et al.
Publicado: (2023)

Stable insulin secreting ducts formed by reprogramming of cells in the liver using a three gene cocktail and a PPAR agonist
por: Banga, Anannya, et al.
Publicado: (2013)

The Role of PPAR-γ and Its Interaction with COX-2 in Pancreatic Cancer
por: Eibl, Guido
Publicado: (2008)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qclblq0rlic2q2c4m8r8nu9bo3